IPN N logo

Ipsen BMV:IPN N Stock Report

Last Price

Mex$1.94k

Market Cap

Mex$177.1b

7D

0%

1Y

n/a

Updated

14 Jul, 2024

Data

Company Financials +

IPN N Stock Overview

Operates as a biopharmaceutical company worldwide. More details

IPN N fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Ipsen S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ipsen
Historical stock prices
Current Share Price€1,936.56
52 Week High€1,936.56
52 Week Low€1,936.56
Beta0.62
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO13.00%

Recent News & Updates

Recent updates

Shareholder Returns

IPN NMX PharmaceuticalsMX Market
7D0%0.8%0.8%
1Yn/a-19.2%-12.3%

Return vs Industry: Insufficient data to determine how IPN N performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how IPN N performed against the MX Market.

Price Volatility

Is IPN N's price volatile compared to industry and market?
IPN N volatility
IPN N Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement4.0%
10% most volatile stocks in MX Market6.8%
10% least volatile stocks in MX Market2.7%

Stable Share Price: IPN N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine IPN N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19295,325David Loewwww.ipsen.com

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
IPN N fundamental statistics
Market capMex$177.15b
Earnings (TTM)Mex$11.86b
Revenue (TTM)Mex$63.54b

14.9x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPN N income statement (TTM)
Revenue€3.31b
Cost of Revenue€571.20m
Gross Profit€2.74b
Other Expenses€2.12b
Earnings€617.10m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Jul 25, 2024

Earnings per share (EPS)7.47
Gross Margin82.72%
Net Profit Margin18.66%
Debt/Equity Ratio9.6%

How did IPN N perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

16%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/14 16:46
End of Day Share Price 2024/04/16 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ipsen S.A. is covered by 36 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Charles Pitman-KingBarclays
Hae Won NaBerenberg